Federal vaccine advisers are gearing up for a pivotal vote this week on whether the 2026–27 COVID-19 shots should be reformulated to target the XFG subvariant, nicknamed "Stratus." The decision will guide which strain manufacturers build into the next booster campaign and what clinics and pharmacies are able to offer later this year, with public health officials, vaccine makers and millions of Americans watching closely.
Advisers to the U.S. Food and Drug Administration are set to debate and vote on an XFG-focused update, according to reporting by Reuters. The advisory committee is expected to take its final vote on the 2026–27 formula on Thursday.
Panel Meeting And Process
The Vaccines and Related Biological Products Advisory Committee will meet in open session on Thursday to recommend a 2026–27 COVID-19 vaccine composition, and the FDA plans to webcast the proceedings. Background materials are slated to be posted before the session, and the panel’s guidance is advisory, not legally binding, although it frequently shapes the decisions of the agency and manufacturers, according to the FDA.
Why XFG Is Under Consideration
Researchers say XFG carries mutations that help it sidestep antibody responses, even though it appears less efficient at entering cells. That combination complicates the annual strain-selection debate. The mix of relative immune escape with only modest cell-entry efficiency is one reason scientists have highlighted both XFG and NB.1.8.1, also called "Nimbus," as leading candidates for the next booster formulation, according to Stony Brook Medicine.
WHO Advice And Manufacturer Readiness
Earlier this month the World Health Organization recommended that manufacturers prioritize LP.8.1 for vaccine antigen selection, while noting that other antigens such as XFG or NB.1.8.1 could also be used. Industry briefings indicate manufacturers say they can produce an XFG-matched vaccine if the committee points in that direction. U.S. Centers for Disease Control and Prevention data cited in coverage estimated that XFG accounted for a majority of U.S. cases in the four-week period ending April 11, strengthening the argument for a targeted update, according to reporting by Reuters.
What To Expect
If the FDA ultimately follows the panel’s recommendation, vaccine makers would pivot production to the chosen strain, while public health agencies map out distribution plans and eligibility guidance ahead of the fall respiratory season. Local coverage, including reporting by FOX 13 Tampa Bay, notes that the vote comes shortly after leadership changes at the agency in May, when Commissioner Marty Makary resigned and Kyle Diamantas stepped in as acting commissioner. Health officials say that for individuals, staying current on recommended vaccines and checking in with a healthcare provider remain the key moves.
The committee’s debate and vote are expected to shape the booster lineup for millions of people heading into late 2026 and 2027. The outcome, and the FDA’s final guidance, will clarify which version of the virus the next round of COVID-19 shots will be built to confront.
